Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fox Corp Class B (FOX) vs Viatris Inc (VTRS) Price & Performance

Fox Corp Class BTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Fox Corp Class B vs Viatris Inc — how do they compare? Fox Corp Class B trades at $55.42 (market cap $25.05B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Fox Corp Class B is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.

FOXVTRS
Market Cap
$25.05B$18.69B
Sector
MediaHealth
52-Week High
$67.76$17.86
52-Week Low
$44.39$9.49
Enterprise Value
$28.41B$30.81B
Dividend Yield
1.03%2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Fox Corp Class B

FOX stock trades at $57.03, up 3.0% in 24 hours, reflecting strong momentum. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 underscore robust performance, with revenue reaching $16.30 billion in 2025. Technical indicators signal bullish trends, supported by moving averages, while RSI levels suggest potential overbought conditions. The company maintains solid profitability with a net income margin of 9.84% and ROE of 14.29%, though valuation metrics like P/E of 14.84 appear reasonable relative to peers.

Outlook remains positive driven by ad demand and digital growth, including Tubi and FOX One initiatives. Risks include reliance on advertising cycles and competitive pressures. Analyst consensus leans neutral with 42.86% buy ratings, but recent news highlights operational strength. Investors should weigh earnings consistency against market volatility and sector headwinds.

Viatris Inc

Viatris (VTRS) trades at $16.43, up 0.86% with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, with revenues rising 5% year-over-year. However, fundamental challenges persist with negative net income margin (-2.79%) and elevated P/E ratio (236.2). Recent developments include FDA approval for Gwyn Lo contraceptive patch and strategic divestitures to sharpen focus.

While Viatris shows operational improvements with consistent cash flow generation, the stock faces headwinds from profitability challenges and high valuation multiples. The mixed analyst sentiment (30.77% buy rating) reflects uncertainty about the company's turnaround trajectory. Key risks include ongoing margin pressure and competitive threats in the generic pharmaceutical space.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Fox Corp Class B

Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.

Read more on FOX

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS